DStruBTarget: Integrating Binding Affinity with structure similarity for ligand binding protein prediction.
Identification of drug binding proteins is an important issue for drug development. Most of the current computational approach is developed only utilizing drug structure similarity. However, the drug structure similarity has failed to reflect the binding quality between the drug and the target protein, which limited the performance of current methods. The present study integrated 2-dimensions (2D) and 3-dimensions (3D) drug structure similarity between query drug and template drugs with known drug-protein binding affinity to identify proteins binding with the query drug. This method is named as DStruBTarget. The performance of DStruBTarget was evaluated by 10-fold cross validation in a dataset containing 9,197 drugs and 1,111 drug binding proteins (DBD dataset). This dataset was constructed by excluding the drugs with similar structures and the proteins high identify with others. The DStruBTarget achieved Hit Rate of 77% in top1 prediction, which is 4.80% and 3.00% better than the methods only using 2D structure similarity, and the method integrating 2D and 3D structure similarity (2D +3D), respectively. The independent test of DStruBTarget was performed in a public available dataset constructed by SwissTargetPrediction. In this dataset, the top 1 Hit Rate of DStruBTarget reached 44.02% that was better than the SwissTargetPrediction, and also outstands other methods, 2D, 3D, 2D + 3D, 2D integrating binding affinity (2D +BA), and 3D integrating binding affinity (3D + BA). DStruBTarget was compared to another newly published method HitPickV2, and achieved 53.8% in Hit Rate of the top one prediction, which was significantly better than the result 32.1% of HitpickV2. Finally, DStruBTarget was integrated with protein BLAST to predict the drug binding proteins not limited in a certain database. DStruBTarget with BLAST was tested in the DBD dataset. The top1 Hit Rate of it was 51.15% that was lower than DStruBTarget without BLAST. Further comparison was on the drugs that bind to multiple numbers of proteins, which illustrated that DStruBTarget with BLAST performed better than without BLAST when the number of binding proteins of the query drugs larger than six. Meanwhile, the prediction power of the DStruBTarget with BLAST in top 1 prediction was found positively correlated with the numbers of proteins binding with the query drugs, while the top 1 prediction power of DStruBTarget without BLAST was negatively correlated with the numbers of binding protein for query drugs. Thus, DStruBTarget with BLAST is a potentially useful approach for predicting novel proteins for drugs that bind to multiple proteins. https://github.com/fanc232/DStruBTarget.